Drugs bill to soar by €30m

The HSE is faced with an unplanned €30m bill for providing drugs not contained in its national service plan for 2012.

A significant part of the cost, between €8m to €10m, will be in providing two Hepatitis C drugs, Boceprevir and Telaprevir.

The drugs were made available in June following the intervention of the Department of Health.